These synergistic drug effects were seen in imatinib-sensitive as well as in imatinib-resistant ALL cells, supporting the notion that Hsp32 may be an attractive new therapeutic target in this disease. The gene discussed is HMOX1; the disease is acute lymphoblastic leukemia.